5021.64

Less: Excise Duty

61.04

Net Sales

4960.60

b) Other Operating Income

285.47

Total Operating Income (a+b)

5246.07

a) (Increase)/decrease in
     Stock-in-trade and work in progress

(113.55)

b) Consumption of Materials

1892.18

c) Purchase of Traded Goods

588.04

d) Employee Cost

317.00

e) Depreciation

170.60

f) Other Expenditure

1530.02

g) Total

4384.29

861.78

69.02

930.80

33.96

896.84

1.32

-

895.52

Tax Expense
a) Current Tax
b) Deferred Tax
c) Fringe Benefit Tax

 
101.00
15.00
8.50

771.02

155.46

Reserves excluding Revaluation
Reserves as per Balance Sheet of previous
Accounting Year

5741.03

4183.37

9.92

Public Shareholding
- Number of Shares
- Percentage of Shareholding

462918088
59.56

a) Pledged/Encumbered
     - Number of Shares
     - Percentage of shares (as a % of the total        shareholding of promoter and promoter group)
     - Percentage of shares (as a % of the total share        capital of the Company)

NIL
NIL

NIL

b) Non Encumbered
     - Number of Shares
     - Percentage of shares (as a % of the total         shareholding of promoter and promoter group)
     - Percentage of shares (as a % of the total share         capital of the Company)

306108047
100.00

39.38

1. The Company is essentially in the pharmaceutical business segment.
2. The Directors at their meeting held today recommended payment of dividend of Rs.2 per equity share (face value Rs.2) for the year 2009-2010 amounting to Rs. 160.58 crores.
3. The above results include results of the Company and its wholly owned subsidiary viz., Cipla FZE.
4. In 2003 the Company received notice of demand from the National Pharmaceutical Pricing Authority, Government of India on account of alleged overcharging in respect of certain drugs under the Drug Price Control Order. This was contested before the jurisdictional High courts wherein it was held in favour of the Company. The orders were challenged before the Hon'ble Supreme Court by the Government. The Hon'ble Supreme Court by separate orders restored the matter to the jurisdictional High Court for interpreting the Drug Policy on the basis of directions and principles laid down by them and also restrained the Government from taking any coercive action against the Company.  The Company has been legally advised that on the basis of these orders there is no probability of demand crystalising. Hence no provision is considered necessary in respect of notice of demand aggregating to Rs.1157.12 crores (inclusive of interest) for the period July 1995 to April 2009.
5. The Audited Standalone financial results are available on the Company's website i.e.www.cipla.com. The key standalone financial information for the year 2009 – 2010 are as under:

   a. Turnover: Rs.5411.68 crores (previous year Rs.5021.64 crores )
   b. Profit before tax: Rs.1324.99 crores (previous year Rs.901.31 crores )
   c. Profit after tax: Rs.1081.49 crores (previous year Rs.776.81 crores )

6. *In March 2010, the Company sold its intellectual property rights and technical knowhow of “i-pill”, an emergency contraceptive brand, to Piramal Healthcare Limited for the territory of India at an aggregate consideration of Rs. 95 crores.
7. The paid-up equity share capital stands increased to Rs.160.58 crores (80,29,21,357 equity shares of Rs.2 each) upon allotment of 2,56,30,000 equity shares of Rs.2 each issued at a price of Rs.263.75 (including premium of Rs.261.75) under Qualified Institutions Placement (QIP) during the quarter ended September 2009.
8. The figures of the previous year have been regrouped/recast to render them comparable with the figures of the current year.
9. The Audited Consolidated Statement of assets and liabilities is as under:

(Rs. in crores)
Particulars	Year Ended
	31.03.2010	31.03.2009
Shareholders Funds
(a) Capital	160.58	155.46
(b) Reserves and Surplus	5749.99	4192.34
Loan Funds	5.07	940.24
Deferred Tax Liabilities	179.15	164.15
Total	6094.79	5452.19
Fixed Assets	2695.41	2358.81
Investments	246.41	80.05
Current Assets, Loans and Advances
(a) Inventories	1512.58	1398.32
(b) Sundry Debtors	1566.63	1852.86
(c) Cash and Bank balances	62.06	53.39
(d) Other current assets	57.82	23.45
(e) Loans and Advances	1168.22	894.89
Less: Current Liabilities and Provisions
(a) Liabilities	997.97	1012.87
(b) Provisions	216.37	196.71
Total	6094.79	5452.19

10. The above results after being reviewed by the Audit Committee were approved at the meeting of the Board of Directors held on 15 th June, 2010.